New Four-Target cancer antibody enters human testing
NCT ID NCT05160545
Summary
This is the first human study of an experimental antibody called GNC-035 for people with advanced breast cancer that has spread or returned after standard treatments. The main goal is to find a safe dose by testing it in 36 patients and watching for side effects. Researchers will also check if the treatment shows any early signs of helping control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dongguan People's Hospital
Dongguan, Guangdong, China
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510120, China
-
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China
-
The Third Hospital of Changsha
Changsha, Hunan, China
-
West China Hospital，Sichuan University
Chengdu, Sichuan, China
-
ZhuJiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.